Erythromycin (S24E9)

Erythromycin has been punching above its weight for decades. In this episode, we chart its rise from a soil-derived discovery by Saccharopolyspora erythraea to its position as a foundational macrolide antibiotic. Known for jamming the protein production machinery in bacteria, erythromycin treats everything from strep throat and pneumonia to neonatal eye infections and even gastroparesis. Its ability to speed up gut motility gives it a unique niche outside of traditional antimicrobial roles.

Yet erythromycin’s legacy isn’t just pharmacological—it’s deeply regulatory and economic, too. We dig into its FDA and EMA approval pathways, the importance of GMP, and how different salt forms cater to clinical needs across oral, topical, and injectable products. We also explore manufacturing via microbial fermentation, the market dynamics behind generics, and the global impact on access and affordability. But with widespread use comes resistance, and erythromycin’s story is increasingly tied to the cautionary tale of antimicrobial stewardship. It remains a crucial tool, but one with limitations that demand attention.